Imidazole → 7-{2-Butyl-4-[4-(4-methoxy-phenoxy)-phenyl]-imidazol-1-yl}-1,2,3,4-tetrahydro-isoquinoline hydrochloride

HRID 901730

反応式

HRID 901730 の反応式
[CH3:1][O:2][C:3]1[CH:18]=[CH:17][C:6]([O:7][C:8]2[CH:13]=[CH:12][C:11]([C:14](=O)[CH3:15])=[CH:10][CH:9]=2)=[CH:5][CH:4]=1.BrC(Br)=O.[NH2:23][C:24]1[CH:33]=[C:32]2[C:27]([CH2:28][CH2:29][N:30](C(OC(C)(C)C)=O)[CH2:31]2)=[CH:26][CH:25]=1.N[C:42]([NH2:44])=O.[C:45]([Cl:51])(=O)[CH2:46][CH2:47][CH2:48]C.N1C=CN=C1>>[ClH:51].[CH2:45]([C:42]1[N:23]([C:24]2[CH:33]=[C:32]3[C:27]([CH2:28][CH2:29][NH:30][CH2:31]3)=[CH:26][CH:25]=2)[CH:15]=[C:14]([C:11]2[CH:12]=[CH:13][C:8]([O:7][C:6]3[CH:17]=[CH:18][C:3]([O:2][CH3:1])=[CH:4][CH:5]=3)=[CH:9][CH:10]=2)[N:44]=1)[CH2:46][CH2:47][CH3:48]

参加物

7

実験手順

1-[4-(4-methoxyphenoxy)phenyl]ethan-1-one (1 mmol) was brominated by General Procedure R1. The bromo ketone was condensed with 7-amino-2-Boc-1,2,3,4-tetrahydroisoquinoline following general procedure R2. The aminoketone intermediate was treated with n-pentanoyl chloride accoding to General Procedure R3. The product amide was then subjected to imidazole formation employing general procedure R4. The BOC group of the product was removed employing general procedure T1 to afford 7-{2-butyl-4-[4-(4-methoxy-phenoxy)-phenyl]-imidazol-1-yl}-1,2,3,4-tetrahydro-isoquinoline hydrochloride (yield 135 mg)

後処理

  1. customThe BOC group of the product was removed

出典と根拠

ORDレコード
ord-503f28d248d741fea4ad252fc2b0d3a5
出典データセット
uspto-grants-2008_04
特許番号
US07361678B2

関連ノート

読み込み中…